Claritev Corp

CTEV remains in a healthy medium-term uptrend with clear higher highs and lows supported by rising EMAs. However, extreme overbought conditions near the 52-week high advise patience. Execution is best deferred to a shallow pullback into the 9/20EMA support zone to align with trend and momentum.

• ↑Q2 revenue $257.5M, +6.6% YoY, highest in 3+ years
• ↑Bookings (ACV) reached $74M YTD, +150% YoY
• ↓Profit margins squeezed by 8–10% medical inflation